AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16917623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 15316606 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg orally, twice daily)
Number of subjects: 40
Study 15316606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11165354 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable measurements
Number of subjects: 72
Study 11165354 — intervention group
Group type: COMPARATOR
Intervention: Controllable measurements
Number of subjects: 72
Study 11165354 — intervention group
Group type: COMPARATOR
Intervention: Predictable measurements
Number of subjects: 72
Study 9295094 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs (Cys or Ser alleles at codon 23 of the 5-HT2C receptor gene)
Number of subjects: 242
Study 9295094 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs with aura
Number of subjects: 242
Study 9295094 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs (men and women analyzed separately)
Number of subjects: 242
Study 9295094 — intervention group
Group type: COMPARATOR
Intervention: Controls (non-migraineurs)
Number of subjects: 242
Study 8331120 — intervention group
Group type: EXPERIMENTAL
Intervention: Butel stem
Number of subjects: 56
Study 8331120 — intervention group
Group type: COMPARATOR
Intervention: PCA design
Number of subjects: 56
Study 31144836 — intervention group
Group type: EXPERIMENTAL
Intervention: MET + CBT + Exercise
Number of subjects: 37
Study 31144836 — intervention group
Group type: COMPARATOR
Intervention: MET + CBT
Number of subjects: 37
Study 31227537 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (twice a week 1‐hour aerobic and strength exercises supervised by a physiotherapist and twice a week 1‐hour Nordic or power walking)
Number of subjects: 180
Study 31227537 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintain habitual activity pattern during 6 months)
Number of subjects: 180
Study 31227537 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 180
Study 31227537 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 28986667 — intervention group
Group type: EXPERIMENTAL
Intervention: PR oxycodone/naloxone
Number of subjects: 20
Study 28986667 — intervention group
Group type: COMPARATOR
Intervention: PR oxycodone plus macrogol 3350
Number of subjects: 20
Study 25917260 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia used in 51 (41%) patients
Number of subjects: 133
Study 25917260 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 133
Study 23767700 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive norms
Number of subjects: 1607
Study 23767700 — intervention group
Group type: EXPERIMENTAL
Intervention: Injunctive norms
Number of subjects: 1607
Study 22393338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest compression
Number of subjects: 34
Study 22393338 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure mask
Number of subjects: 34
Study 18384087 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (VSL#3) for pouchitis
Number of subjects: 0
Study 18384087 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Escherichia coli Nissle 1917) for ulcerative colitis
Number of subjects: 0
Study 18384087 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics for Crohn's disease
Number of subjects: 0
Study 18384087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary ecological treatments for IBD
Number of subjects: 0
Study 16649224 — intervention group
Group type: EXPERIMENTAL
Intervention: XPD *A haplotype
Number of subjects: 108
Study 12826988 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 14
Study 12826988 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 15 mg
Number of subjects: 14
Study 12826988 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 14
Study 12826988 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 75 mg
Number of subjects: 14
Study 12826988 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian 400 mg and 800 mg
Number of subjects: 14
Study 12826988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11392165 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome patients
Number of subjects: 37
Study 8841951 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine
Number of subjects: 0
Study 8841951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1503379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (3 g/day intravenously) + Rifaximin (1200 mg/day P.O.)
Number of subjects: 30
Study 1503379 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (3 g/day intravenously)
Number of subjects: 30
Study 6423365 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined methimazole-lithium therapy
Number of subjects: 0
Study 6423365 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy of methimazole
Number of subjects: 0
Study 31553468 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence (interoception and attention module)
Number of subjects: 362
Study 31553468 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect (compassion module)
Number of subjects: 362
Study 31553468 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective (perspective taking module)
Number of subjects: 362
Study 31553468 — intervention group
Group type: COMPARATOR
Intervention: Retest control (no training)
Number of subjects: 362
Study 29381229 — intervention group
Group type: EXPERIMENTAL
Intervention: Codrituzumab exposure of ≥230 μg ml-1 and high CD16MESF level (>5.26 × 105 MESF at least)
Number of subjects: 181
Study 26107538 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated lumbar extension exercise intervention (1×/week for 12 weeks, single set to momentary muscular failure using a load equal to 80% max tested torque)
Number of subjects: 24
Study 26107538 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control period
Number of subjects: 24
Study 25142870 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative management (PPCM)
Number of subjects: 126
Study 22751603 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg
Number of subjects: 405
Study 22751603 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg
Number of subjects: 405
Study 22751603 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 405
Study 22751603 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab (both doses)
Number of subjects: 405
Study 22751603 — intervention group
Group type: COMPARATOR
Intervention: placebo (crossover to golimumab)
Number of subjects: 405
Study 21104449 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacylglycerol (DAG) supplementation
Number of subjects: 298
Study 21104449 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 298
Study 17495203 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based group
Number of subjects: 284
Study 17495203 — intervention group
Group type: EXPERIMENTAL
Intervention: Correspondence course
Number of subjects: 284
Study 17495203 — intervention group
Group type: COMPARATOR
Intervention: Information-only control
Number of subjects: 284
Study 15158303 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition (GLN)
Number of subjects: 38
Study 15158303 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous enteral control (Con)
Number of subjects: 38
Study 15158303 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GLN and Con)
Number of subjects: 38
Study 11668229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal onlay mesh repair without cauterization (Group A)
Number of subjects: 51
Study 11668229 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal onlay mesh repair with cauterization (Group B)
Number of subjects: 51
Study 9520587 — intervention group
Group type: EXPERIMENTAL
Intervention: Information received from a physician
Number of subjects: 737
Study 9520587 — intervention group
Group type: COMPARATOR
Intervention: Information received through other channels (e.g., weekly magazines)
Number of subjects: 737
Study 9520587 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher level of education
Number of subjects: 737
Study 9520587 — intervention group
Group type: COMPARATOR
Intervention: Lower level of education
Number of subjects: 737
Study 7992904 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index
Number of subjects: 44
Study 7992904 — intervention group
Group type: COMPARATOR
Intervention: Power spectral variables (95% spectral edge, median frequency, relative delta power)
Number of subjects: 44
Study 7992904 — intervention group
Group type: COMPARATOR
Intervention: Plasma propofol concentrations
Number of subjects: 44
Study 2914153 — intervention group
Group type: EXPERIMENTAL
Intervention: iv placebo
Number of subjects: 22
Study 2914153 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 subjects)
Number of subjects: 22
Study 30974986 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 1600
Study 30974986 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U300
Number of subjects: 1600
Study 27701901 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about cognitive problems after chemotherapy with reassuring information
Number of subjects: 175
Study 27701901 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about cognitive problems after chemotherapy without reassuring information
Number of subjects: 175
Study 27701901 — intervention group
Group type: COMPARATOR
Intervention: No information about chemotherapy-related cognitive problems (control group)
Number of subjects: 175
Study 25902515 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality foster care intervention (n = 48)
Number of subjects: 138
Study 25902515 — intervention group
Group type: COMPARATOR
Intervention: Institutional care (n = 43)
Number of subjects: 138
Study 25902515 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention (n = 48)
Number of subjects: 138
Study 23572323 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg after each haemodialysis session)
Number of subjects: 40
Study 23572323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg after each haemodialysis session)
Number of subjects: 40
Study 23572323 — intervention group
Group type: COMPARATOR
Intervention: Control (pretreatment values)
Number of subjects: 40
Study 20978247 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 50 μg/kg
Number of subjects: 50
Study 20978247 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 50
Study 19328860 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM)
Number of subjects: 368
Study 16942566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a weekly dose of 200,000 SQ-U
Number of subjects: 30
Study 16942566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a weekly dose of 24,000 SQ-U
Number of subjects: 30
Study 16942566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12749277 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine alone
Number of subjects: 63
Study 12749277 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ranitidine and ecabet
Number of subjects: 63
Study 10811145 — intervention group
Group type: EXPERIMENTAL
Intervention: Estriol (E3) treatment (2 mg/day) for 30 weeks
Number of subjects: 24
Study 10811145 — intervention group
Group type: COMPARATOR
Intervention: Control group (CaCl2 without estriol)
Number of subjects: 24
Study 8626978 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin 10%
Number of subjects: 15
Study 8626978 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin 20%
Number of subjects: 15
Study 8626978 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin 30%
Number of subjects: 15
Study 8626978 — intervention group
Group type: COMPARATOR
Intervention: Glycerin 0% (diluent)
Number of subjects: 15
Study 8626978 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glycerin dose (volume x concentration)
Number of subjects: 15
Study 8626978 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin (0% to 30%)
Number of subjects: 15
Study 1445476 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine 500 mg orally, 3 times a day for 180 days
Number of subjects: 60
Study 1445476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3904818 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stress antepartum cardiotocography (revealed group)
Number of subjects: 396
Study 3904818 — intervention group
Group type: COMPARATOR
Intervention: Control group (withheld cardiotocograph recordings)
Number of subjects: 396
Study 31094126 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral progesterone (dydrogesterone) 10 mg twice daily
Number of subjects: 152
Study 31094126 — intervention group
Group type: COMPARATOR
Intervention: Micronized progesterone (cyclogest pessary) 400 mg daily per rectal use
Number of subjects: 152
Study 28716618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group viewed a telenovela about caregiving during a one-hour audiovisual seminar.
Number of subjects: 142
Study 28716618 — intervention group
Group type: COMPARATOR
Intervention: Control group viewed a control video during a one-hour audiovisual seminar.
Number of subjects: 142
Study 25050521 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab and etanercept combination therapy
Number of subjects: 315
Study 25050521 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 315
Study 25050521 — intervention group
Group type: COMPARATOR
Intervention: Control group (joint pains without rheumatoid arthritis)
Number of subjects: 315
Study 23490403 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise withdrawal of NIV
Number of subjects: 60
Study 23490403 — intervention group
Group type: COMPARATOR
Intervention: Immediate withdrawal of NIV
Number of subjects: 60
Study 20886606 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose imatinib (800 mg/d) with pegylated interferon alpha-2b (0.5 μg/kg/wk) and GM-CSF (125 mg/m² 3× weekly)
Number of subjects: 94
Study 20886606 — intervention group
Group type: COMPARATOR
Intervention: High-dose imatinib (800 mg/d) alone
Number of subjects: 94
Study 20886606 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose imatinib (800 mg/d) with pegylated interferon alpha-2b and GM-CSF
Number of subjects: 94
Study 19616196 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust mood induction
Number of subjects: 120
Study 19616196 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety mood induction
Number of subjects: 120
Study 19616196 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 120
Study 19616196 — intervention group
Group type: COMPARATOR
Intervention: Happy mood induction
Number of subjects: 120
Study 19616196 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-related interpretation bias
Number of subjects: 120
Study 17855184 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0
Study 17855184 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin
Number of subjects: 0
Study 15150203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab (2.0 mg/kg bolus plus 0.05 mg/kg per hour for 24 hours; n = 1553)
Number of subjects: 3099
Study 15150203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1546)
Number of subjects: 3099
Study 15150203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab (n = 1547)
Number of subjects: 3099
Study 15150203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1535)
Number of subjects: 3099
Study 11212974 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg)
Number of subjects: 166
Study 11212974 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (10-20 mg)
Number of subjects: 166
Study 9774932 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 0
Study 9423108 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 30
Study 9423108 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (4 mg/kg)
Number of subjects: 30
Study 9423108 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 30
Study 2685007 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human GH therapy (Norditropin; 2 IU/m2.day)
Number of subjects: 22
Study 5067671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot drink of milk
Number of subjects: 0
Study 5067671 — intervention group
Group type: EXPERIMENTAL
Intervention: Horlicks
Number of subjects: 0
Study 5067671 — intervention group
Group type: COMPARATOR
Intervention: Hot water
Number of subjects: 0
Study 30989330 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 400 mg once daily
Number of subjects: 487
Study 30989330 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 487
Study 29118371 — intervention group
Group type: EXPERIMENTAL
Intervention: MIR137 SNP rs1625579
Number of subjects: 736
Study 29118371 — intervention group
Group type: COMPARATOR
Intervention: CPLX1 expression
Number of subjects: 736
Study 29118371 — intervention group
Group type: COMPARATOR
Intervention: allele and genotype frequencies of studied SNPs
Number of subjects: 736
Study 25092775 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 6) once every 3 weeks for four cycles
Number of subjects: 443
Study 25092775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg) once every 2 weeks for nine cycles
Number of subjects: 443
Study 25092775 — intervention group
Group type: COMPARATOR
Intervention: Standard neoadjuvant chemotherapy (paclitaxel followed by ddAC)
Number of subjects: 443
Study 23114287 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous creatine phosphate added to cardioplegic solution
Number of subjects: 24
Study 23114287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no creatine phosphate)
Number of subjects: 24
Study 20810254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy with transference interpretation
Number of subjects: 46
Study 20810254 — intervention group
Group type: COMPARATOR
Intervention: Dynamic psychotherapy without transference interpretation
Number of subjects: 46
Study 19459146 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-modulating nutrition (IMN) formula
Number of subjects: 15
Study 19459146 — intervention group
Group type: COMPARATOR
Intervention: Standard stress formula (relative comparison group)
Number of subjects: 15
Study 16770612 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm exercise during pressure support ventilation
Number of subjects: 8
Study 16770612 — intervention group
Group type: COMPARATOR
Intervention: Arm exercise during trach collar (unassisted respiration)
Number of subjects: 8
Study 16770612 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced dyspnea and arm discomfort
Number of subjects: 8
Study 15544576 — intervention group
Group type: EXPERIMENTAL
Intervention: TPH1 gene polymorphism (T27224C)
Number of subjects: 206
Study 15544576 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-allele haplotypes involving T27224C polymorphism
Number of subjects: 206
Study 15544576 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression, anxiety, and comorbid depression and anxiety disorders
Number of subjects: 206
Study 11153670 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 300-450 mg daily
Number of subjects: 2288
Study 11153670 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice daily
Number of subjects: 2288
Study 11153670 — intervention group
Group type: COMPARATOR
Intervention: Combination of rifabutin and clarithromycin
Number of subjects: 2288
Study 11153670 — intervention group
Group type: COMPARATOR
Intervention: No MAC prophylaxis
Number of subjects: 2288
Study 9286780 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 infusion
Number of subjects: 18
Study 9286780 — intervention group
Group type: COMPARATOR
Intervention: Prostacyclin infusion
Number of subjects: 18
Study 8365299 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms, Salbutamol 400 micrograms, Ipratropium Bromide 80 micrograms
Number of subjects: 9
Study 8365299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide 80 micrograms, Salbutamol 200 micrograms, Salbutamol 400 micrograms
Number of subjects: 9
Study 8365299 — intervention group
Group type: COMPARATOR
Intervention: Maximal doses of Ipratropium Bromide (80 micrograms)
Number of subjects: 9
Study 6810527 — intervention group
Group type: EXPERIMENTAL
Intervention: Total orchidectomy
Number of subjects: 22
Study 6810527 — intervention group
Group type: COMPARATOR
Intervention: Subcapsular orchidectomy
Number of subjects: 22
Study 31394770 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus directed forgetting (Ex + DF)
Number of subjects: 60
Study 31394770 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed forgetting only (DF)
Number of subjects: 60
Study 31394770 — intervention group
Group type: COMPARATOR
Intervention: Remember only (R)
Number of subjects: 60
Study 28115474 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 300 units/mL (Gla‐300)
Number of subjects: 59
Study 24993934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily (arm A)
Number of subjects: 23
Study 24993934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg plus bicalutamide 50 mg daily (arm B)
Number of subjects: 23
Study 24993934 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 23
Study 24462367 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals supplemented with 1.4 g of cocoa extract (645.3 mg of polyphenols)
Number of subjects: 50
Study 24462367 — intervention group
Group type: COMPARATOR
Intervention: Control meals within a 15% energy restriction diet
Number of subjects: 50
Study 22968185 — intervention group
Group type: EXPERIMENTAL
Intervention: nonsurgical approach to ground-glass nodules (GGNs)
Number of subjects: 56